Preclinical CRO Market: Analyzing The Impact Of Technology On Research Efficiency

The global preclinical CRO market, valued at USD 5.72 billion in 2023, is projected to grow at a CAGR of 8.7% from 2024 to 2030. The increased R&D budget for drug development is driving the rising demand for preclinical contract research organization (CRO) services, fueling market growth. The surge in preclinical trials involving large molecules and the need to reduce R&D expenses are further contributing to the growing demand for quality preclinical CRO services.

 

The rapid pace of preclinical studies for COVID-19 vaccines highlights the crucial role of CROs. Increasing spending on CRO services is expected to significantly boost market growth during the forecast period. The growing demand for drugs post-COVID-19, coupled with significant funding from organizations like the U.S. federal government for R&D of therapeutics and medical devices, is further contributing to market expansion.

 

Gather more insights about the market drivers, restrains and growth of the Preclinical CRO Market 

 

Regional Insights:

 

North America Electric Motor Market Trends

North America accounted for the largest share of 47.2% in 2023 owing to the presence of established CROs specializing in early drug discovery, such as Charles River Laboratories and LabCorp. The U.S. is the biggest market for preclinical trial outsourcing, as several biopharmaceutical companies prefer outsourcing their preclinical trials to CROs based in the U.S., to seek benefit from the Investigational New Drug (IND) application, approved by the FDA.

U.S.

The U.S. accounted for the highest share in the global preclinical trial outsourcing market as a large number of pharmaceutical and life sciences companies are present in this region. CROs in the country possess various capabilities such as genotoxicity and immunotoxicity testing services, which are majorly carried out in the U.S. Along with this, rapid growth in emerging areas of medicine such as personalized medicines, orphan drugs, and biosimilar is expected to propel growth of the preclinical trial outsourcing market in the U.S.

 

Asia Pacific Electric Motor Market Trends

Asia Pacific is also anticipated to grow at the fastest rate of 11.6% during the forecast period. The changing business model of MNC outsourcing and the rising cost of R&D is expected to increase preclinical outsourcing in the Asia Pacific, owing to the cost efficiency offered by CROs in countries such as India and China. Established companies located in Western Europe and the U.S. pursue analytical services, site research development, and clinical activities in the Asia Pacific region in order to reduce the cost associated with research.

Japan

Japan is considered to be one of the largest pharmaceutical markets across the globe. The growing pharmaceutical industry in Japan is contributing to the increasing demand for preclinical trial outsourcing. There has been a significant increase in the number of clinical trials being conducted in the country as the Japanese government is undertaking steps to offer regulatory support and promote clinical trials in the country. This is expected to stimulate the market for preclinical services as preclinical testing requires to be conducted in proximity to central development centers.

India

Preclinical CRO in India:The preclinical CRO market in India has experienced significant growth, driven by its cost advantage, a skilled workforce, and a favorable regulatory environment. Indian CROs offer competitive pricing, attracting international pharmaceutical and biotech companies seeking to outsource preclinical research.

 

Browse through Grand View Research's Category Medical Devices Industry Research Reports.

 

• The global automated suturing devices market size was valued at USD 3.63 billion in 2023 and is expected to expand at a CAGR of 7.3% from 2024 to 2030.  

• The global probe reprocessing market size was valued at USD 844.87 million in 2024 and is anticipated to grow at a CAGR of 10.55 % from 2025 to 2030.

 

Key Companies & Market Share Insights

The preclinical CRO market is diverse, encompassing both large, multinational CROs like Labcorp, Charles River Labs, Eurofins Scientific, and Intertek Group, and smaller, specialized CROs. Market share in this sector is influenced by factors such as the number of players, service portfolio, therapeutic expertise, geographic reach, innovation, investments, and strategic partnerships. For example, Covance, a leading drug development business under Labcorp, offers a comprehensive suite of preclinical services, including pharmacology & safety assessment, vector & cell characterization & qualification, and biodistribution testing & services. These market players often specialize in specific therapeutic areas or emerging fields like immuno-oncology and gene therapy. Their broad geographic reach enables them to provide clients with access to diverse patient populations, regulatory environments, and research expertise. 

Key Preclinical CRO Companies:

• Eurofins Scientific
• PRA Health Sciences, Inc.
• Wuxi AppTec
• Medpace, Inc.
• Charles River Laboratories International, Inc.
• PPD (Thermo Fisher Scientific, Inc.)
• SGA SA
• Intertek Group Plc (IGP)
• LABCORP
• Crown Bioscience

 

Order a free sample PDF of the Preclinical CRO Market Intelligence Study, published by Grand View Research.